CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 69 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,378,722 | -55.6% | 5,228,461 | -20.7% | 0.18% | -54.7% |
| Q1 2024 | $14,378,846 | +40.6% | 6,595,801 | 0.0% | 0.40% | +54.3% |
| Q4 2023 | $10,223,492 | +20.2% | 6,595,801 | 0.0% | 0.26% | +11.8% |
| Q3 2023 | $8,508,583 | -25.0% | 6,595,801 | 0.0% | 0.23% | -27.5% |
| Q2 2023 | $11,344,778 | +13.9% | 6,595,801 | 0.0% | 0.32% | -13.2% |
| Q1 2023 | $9,959,660 | -5.6% | 6,595,801 | 0.0% | 0.36% | -18.2% |
| Q4 2022 | $10,553,282 | +10.3% | 6,595,801 | 0.0% | 0.44% | +12.7% |
| Q3 2022 | $9,564,000 | -10.0% | 6,595,801 | +13.6% | 0.40% | -23.0% |
| Q2 2022 | $10,621,000 | -31.5% | 5,803,700 | 0.0% | 0.51% | -17.3% |
| Q1 2022 | $15,496,000 | -38.3% | 5,803,700 | 0.0% | 0.62% | -32.0% |
| Q4 2021 | $25,130,000 | -41.7% | 5,803,700 | +4.1% | 0.91% | -43.6% |
| Q1 2021 | $43,106,000 | +18.0% | 5,576,471 | 0.0% | 1.62% | +12.5% |
| Q4 2020 | $36,526,000 | +54.3% | 5,576,471 | +56.7% | 1.44% | +11.5% |
| Q3 2020 | $23,672,000 | -8.8% | 3,559,722 | +14.3% | 1.29% | -19.4% |
| Q2 2020 | $25,952,000 | -13.7% | 3,115,537 | -20.6% | 1.60% | -42.9% |
| Q1 2020 | $30,082,000 | +372.5% | 3,921,973 | +411.9% | 2.80% | +480.5% |
| Q4 2019 | $6,367,000 | -54.0% | 766,148 | -59.2% | 0.48% | -66.8% |
| Q3 2019 | $13,853,000 | -34.1% | 1,877,148 | +0.2% | 1.46% | -36.6% |
| Q2 2019 | $21,022,000 | +63.2% | 1,873,617 | +56.4% | 2.30% | +59.2% |
| Q1 2019 | $12,879,000 | -45.7% | 1,198,000 | +6.5% | 1.44% | -49.6% |
| Q4 2017 | $23,738,000 | -41.4% | 1,124,483 | -49.6% | 2.86% | -44.4% |
| Q3 2017 | $40,535,000 | +29.0% | 2,230,898 | +10.1% | 5.15% | +5.6% |
| Q2 2017 | $31,418,000 | +0.8% | 2,026,998 | +12.3% | 4.88% | -8.0% |
| Q1 2017 | $31,167,000 | +411.2% | 1,804,675 | +225.3% | 5.30% | +332.7% |
| Q4 2016 | $6,097,000 | -34.3% | 554,806 | -6.3% | 1.22% | -30.0% |
| Q3 2016 | $9,280,000 | +49.9% | 591,813 | -2.4% | 1.75% | +32.6% |
| Q2 2016 | $6,192,000 | -20.8% | 606,138 | 0.0% | 1.32% | -31.8% |
| Q1 2016 | $7,819,000 | -38.5% | 606,138 | -0.4% | 1.94% | -10.7% |
| Q4 2015 | $12,707,000 | – | 608,848 | – | 2.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners IX LLC | 4,244,381 | $43,378,000 | 100.00% |
| VHCP Management II, LLC | 577,831 | $5,905,000 | 3.56% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 71,366 | $729,000 | 2.45% |
| Casdin Capital, LLC | 234,179 | $2,392,000 | 2.38% |
| BVF INC/IL | 606,138 | $6,192,000 | 1.32% |
| Opaleye Management Inc. | 160,000 | $1,634,000 | 1.09% |
| Redmile Group, LLC | 733,899 | $7,497,000 | 0.72% |
| VHCP Management, LLC | 64,200 | $656,000 | 0.68% |
| Montecito Bank & Trust | 146,544 | $1,497,000 | 0.63% |
| Cormorant Asset Management, LP | 371,636 | $3,796,000 | 0.54% |